- Home
- SLGN vs KALA Comparison
SLGN vs KALA Comparison
Compare SLGN & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLGN
- KALA
- Stock Information
- Founded
- SLGN 1987
- KALA 2009
- Country
- SLGN United States
- KALA United States
- Employees
- SLGN N/A
- KALA N/A
- Industry
- SLGN Containers/Packaging
- KALA Biotechnology: Pharmaceutical Preparations
- Sector
- SLGN Industrials
- KALA Health Care
- Exchange
- SLGN Nasdaq
- KALA Nasdaq
- Market Cap
- SLGN 5.8B
- KALA 26.2M
- IPO Year
- SLGN 1997
- KALA 2017
- Fundamental
- Price
- SLGN $55.26
- KALA $5.70
- Analyst Decision
- SLGN Strong Buy
- KALA Strong Buy
- Analyst Count
- SLGN 9
- KALA 3
- Target Price
- SLGN $63.78
- KALA $14.00
- AVG Volume (30 Days)
- SLGN 637.0K
- KALA 137.4K
- Earning Date
- SLGN 07-30-2025
- KALA 08-05-2025
- Dividend Yield
- SLGN 1.45%
- KALA N/A
- EPS Growth
- SLGN N/A
- KALA N/A
- EPS
- SLGN 2.69
- KALA N/A
- Revenue
- SLGN $6,004,317,000.00
- KALA N/A
- Revenue This Year
- SLGN $12.25
- KALA N/A
- Revenue Next Year
- SLGN $2.65
- KALA N/A
- P/E Ratio
- SLGN $20.57
- KALA N/A
- Revenue Growth
- SLGN 1.99
- KALA N/A
- 52 Week Low
- SLGN $44.37
- KALA $2.92
- 52 Week High
- SLGN $58.14
- KALA $11.20
- Technical
- Relative Strength Index (RSI)
- SLGN 52.34
- KALA 59.39
- Support Level
- SLGN $53.86
- KALA $5.39
- Resistance Level
- SLGN $55.30
- KALA $6.30
- Average True Range (ATR)
- SLGN 0.95
- KALA 0.63
- MACD
- SLGN -0.11
- KALA 0.03
- Stochastic Oscillator
- SLGN 44.03
- KALA 56.00
About SLGN Silgan Holdings Inc.
Silgan Holdings manufactures about half of the metal food containers in North America. Its major customers include Campbell Soup, Nestle, and Del Monte. Silgan's other business segments include plastic dispensers and containers for personal and healthcare products and a closures business that manufactures metal and plastic lids and caps.
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.